Orion Pharma Advances ODM-212 in Phase 1b/2 Basket Trial for Advanced Solid Tumors
Event summary
- Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments for advanced mesothelioma, KRAS G12C mutated NSCLC, and pancreatic cancer.
- Trial includes three cohorts: ODM-212 with ipilimumab and nivolumab for mesothelioma, ODM-212 with sotorasib for NSCLC, and ODM-212 with chemotherapy for pancreatic cancer.
- ODM-212 targets the Hippo signaling pathway, aiming to address treatment resistance in these advanced solid tumors.
- Trial is multi-centre and open-label, designed to evaluate efficacy, safety, dose, and tolerability of ODM-212 combinations.
The big picture
Orion Pharma's initiation of the TEADCO trial underscores the growing focus on combination therapies in oncology, particularly for difficult-to-treat cancers. The trial's design highlights the strategic shift towards addressing treatment resistance, a critical unmet need in advanced solid tumors. With ODM-212 targeting the Hippo signaling pathway, Orion aims to differentiate itself in a market increasingly dominated by targeted and immuno-oncology therapies.
What we're watching
- Clinical Efficacy
- How ODM-212's combination with standard treatments will perform in addressing treatment resistance in advanced solid tumors.
- Regulatory Pathway
- The pace at which Orion Pharma can advance ODM-212 through clinical trials and potential regulatory approvals.
- Market Positioning
- Whether ODM-212 can establish itself as a best-in-class pan-TEAD inhibitor in the competitive oncology market.
Related topics